#### PATENT COOPERATION TREATY

## **PCT**

# Translation INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 346330D21230	FOR FURTHER ACTION	See Form PCT/IPEA/416			
International application No.	International filing date (day/month/year)	Priority date (day/month/year)			
PCT/FR2004/001907	19.07.2004	18.07.2003			
International Patent Classification (IPC) or nation	onal classification and IPC				
A61K35/78, A61K31/56, A61K7/48, A61K7/26, A61P19/02, A61P1/02					
Applicant  LABORATOIRES EXPANSCIENCE					
<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>					
2. This REPORT consists of a total of	5 sheets, include	ng this cover sheet.			
3. This report is also accompanied by A	NNEXES, comprising:				
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:					
sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental					
Box.  b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))					
b (sent to the International	Bureau only) a total of (Indicate type and flum	ber of electronic carrel(s))			
, containing a sequence listing and/or tables					
related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
This report contains indications relations	ing to the following items:				
Box No. I Basis of the	e report				
Box No. II Priority					
Box No. III Non-establ	ishment of opinion with regard to novelty, inve	entive step and industrial applicability			
Box No. IV Lack of uni	ity of invention				
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain do	cuments cited				
Box No. VII Certain def	fects in the international application				
Box No. VIII Certain obs	servations on the international application				
Date of submission of the demand	Date of completion of	this report			
Name and mailing address of the IPEA/EP	Authorized officer				
Facsimile No.	Telephone No.				

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/FR2004/001907

Box No. I	Basis of the report		
indicated und			
which i	port is based on translations from the original language is the language of a translation furnished for the purpo international search (Rule 12.3 and 23.1(b)) sublication of the international application (Rule 12.4)	oses of:	•
	nternational preliminary examination (Rule 55.2 and/o		Link house know from the first of
receiving Off this report):	to the elements of the international application, this to fice in response to an invitation under Article 14 are ernational application as originally filed/furnished scription:	report is based on (replacement sheets w e referred to in this report as "originall"	micn nave been jurnished to the y filed" and are not annexed to
pages	1-28		as originally filed/furnished
pages*			
pages*		•	
the cla			
nos.	1–13		as originally filed/furnished
nos.*	1-13	as amended (together with a	<b>-</b> - ·
nos.*		· · · · · · · · · · · · · · · · · · ·	<del>.</del>
nos.*			
	awings:		ac originally Fladfordi-1-1
sheets			
sheets		received by this Authority on	
sheets		received by this Authority on	
a sequ	nence listing and/or any related table(s) - see Supplem	nental Box Relating to Sequence Listing.	
3. The ar	mendments have resulted in the cancellation of:		
	the description, pages		
	the claims, nos.		
	the drawings, sheets/figs		
	the sequence listing (specify):		<del></del>
	any table(s) related to sequence listing (specify):		
This r	report has been established as if (some of) the amend have been considered to go beyond the disclosure as fi	iments annexed to this report and listed iled, as indicated in the Supplemental Bo	below had not been made, since x (Rule 70.2(c)).
	the description, pages		
	the claims, nos.		
	the drawings, sheets/figs		
	the sequence listing (specify):		
	•		
* If item 4 ap	rplies, some or all of those sheets may be marked "sup	perseded."	

International application No.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY				PCT/FR2004/001907				
Box No. V Reasoned statement under Article 35(2) with regard to novelty, invicitations and explanations supporting such statement			gard to novelty, inven	ntive step or industrial applicability;				
1.	Statement		_					
	Novelt	y (N)	Claims	1-13				YES
			Claims		-		<u>.                                    </u>	_ NO
	Inventi	ve step (IS)	Claims	1-13				YES
			Claims			· · · · · · · · · · · · · · · · · · ·		_ NO
	Industr	ial applicability (IA)	Claims	1-13				_ YES
			Claims					_ NO
2.	Citations	and explanations (Rule	70.7)					
	1.	In the pr	esent	report,	reference	is made to	the	
		following	g docu	ments:				
1								

D1: XP002286368;

D2: WO-A-03/055462;

D3: WO-A-00/62789;

- 2. NOVELTY (PCT Article 33(2))
- The present application fulfils the requirements 2.1 set forth in PCT Article 33(1) because the subject matter of claims 1-13 complies with the requirement of novelty defined in PCT Article 33(2).

Document D1 describes the use of a plant extract derived from Lupinus albus (LU105) in the treatment or prevention of gingival connective tissue degeneration and periodontal diseases such as gingivitis and periodontitis (see the whole document). LU105 designates lupin peptides that are hydrolysed fractions of hydrolysable lupin

International application No.
PCT/FR2004/001907

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

proteins. The lupeol described and used in the present application is, on the other hand, a water-insoluble triterpenic alcohol. It follows that lupin peptides (LU105) and lupeol, which are produced using two different methods, are substances that have no similarity in terms of structure and cellular action. Neither one can contain the other. As a result, lupeol and LU105 (lupin peptides) are two separate substances (see documents D2, page 6, lines 29-31; and D3, page 6).

The subject matter of claims 1-13 is, therefore, novel under the terms of PCT Article 33(2).

- 3. INVENTIVE STEP (PCT Article 33(3))
- 3.1 The present application fulfils the requirements set forth in PCT Article 33(1) because the subject matter of claims 1-13 involves an inventive step as defined in PCT Article 33(3). There is nothing in the prior art to suggest the use of a lupeolrich extract in the treatment or prevention of connective tissue degeneration.

As a result, the subject matter of claims 1-13 involves an inventive step as defined in PCT Article 33(3).

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/FR2004/001907

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
4.	INDUSTRIAL APPLICABILITY (PCT Article 33(4))
4.1	Claims 1-13 comply with the requirement of
	industrial applicability defined in PCT Article
	33(4).